Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

G, Saglio; DW, Kim; S, Issaragrisil; Coutre P, le; G, Etienne; C, Lobo; R, Pasquini; RE, Clark; A, Hochhaus; TP, Hughes; N, Gallagher; A, Hoenekopp; M, Dong; A, Haque; RA, Larson; HM, Kantarjian

doi:10.1056/nejmoa0912614

Public

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Shared by NobleBlocks on Jun 5, 2010 • 12:00 AM UTC

Authors:

Saglio G

Kim DW

Issaragrisil S

Abstract

Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.Methods In t...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!